Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
7.94
+0.20 (2.58%)
Apr 8, 2026, 12:42 PM EDT - Market open
Solid Biosciences Employees
Solid Biosciences had 121 employees as of December 31, 2025. The number of employees increased by 21 or 21.00% compared to the previous year.
Employees
121
Change (1Y)
21
Growth (1Y)
21.00%
Revenue / Employee
n/a
Profits / Employee
-$1,440,702
Market Cap
781.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 121 | 21 | 21.00% |
| Dec 31, 2024 | 100 | 12 | 13.64% |
| Dec 31, 2023 | 88 | 1 | 1.15% |
| Dec 31, 2022 | 87 | -17 | -16.35% |
| Dec 31, 2021 | 104 | 34 | 48.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Maravai LifeSciences Holdings | 435 |
| MeiraGTx Holdings | 403 |
| Kura Oncology | 260 |
| Omeros | 175 |
| Jade Biosciences | 55 |
| Design Therapeutics | 54 |
| Relmada Therapeutics | 17 |
SLDB News
- 1 day ago - Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 27 days ago - Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned - Benzinga
- 27 days ago - Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - GlobeNewsWire
- 4 weeks ago - Solid Biosciences Announces Oversubscribed $240 Million Private Placement - GlobeNewsWire
- 4 weeks ago - Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - GlobeNewsWire
- 5 weeks ago - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy - GlobeNewsWire